Mountain Valley MD (CSE: MVMD) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling with news the company will be conducting a Bio-Safety Level 4 lab study of COVID-19 viral clearance to prove out the Company’s solubilized Ivermectin technology versus commercially available oral form in the time and efficacy in viral clearance.
Farber telling Proactive what that means while Hancock talks about the timing of the study and how excited they are to be doing this one of the kind study.